Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03668041 · ClinicalTrials.gov registry record · Phase 3

National Adaptive Trial for PTSD Related Insomnia

A Phase 3 study of Insomnia, sponsored by VA Office of Research and Development.

Active
Registry status
Phase 3
Development phase
673
Enrollment target
20
Study locations

NCT03668041 is a Phase 3 study of Insomnia that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 673 participants, above the 166-participant average among 151 other Insomnia trials with a reported enrollment target (305% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03668041, a Phase 3 study of Insomnia, is active but no longer recruiting, sponsored by VA Office of Research and Development.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
673 participants
Enrollment target
20
Study locations

Study Summary

Many Veterans with posttraumatic stress disorder (PTSD) have trouble sleeping or have frequent nightmares. So far, no medication has been approved for treatment of insomnia in PTSD. The purpose of this research study is to find out if taking medications called trazodone or eszopiclone can help decrease symptoms of insomnia in patients with PTSD. PTSD is a form of intense anxiety which sometimes results from severe trauma. Symptoms may include nightmares, flashbacks, troublesome memories, difficulty sleeping, poor concentration, irritability, anger, and emotional withdrawal. Insomnia is a disorder that can make it hard to fall sleep, stay asleep or cause a person to wake up too early and not be able to fall back to sleep.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Trazodone
  • DRUG Eszopiclone

Study Locations (20)

California

  • VA Loma Linda Healthcare System, Loma Linda, CA - Loma Linda
  • VA Long Beach Healthcare System, Long Beach, CA - Long Beach
  • VA Palo Alto Health Care System, Palo Alto, CA - Palo Alto
  • VA San Diego Healthcare System, San Diego, CA - San Diego
  • San Francisco VA Medical Center, San Francisco, CA - San Francisco

North Carolina

  • Asheville VA Medical Center, Asheville, NC - Asheville
  • Durham VA Medical Center, Durham, NC - Durham
  • Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC - Salisbury

Alabama

  • Birmingham VA Medical Center, Birmingham, AL - Birmingham
  • Tuscaloosa VA Medical Center, Tuscaloosa, AL - Tuscaloosa

Connecticut

  • VA Connecticut Healthcare System West Haven Campus, West Haven, CT - West Haven
  • CERC (VISN1, West Haven, CT) - West Haven

Arizona

  • Phoenix VA Health Care System, Phoenix, AZ - Phoenix

Florida

  • Bay Pines VA Healthcare System, Pay Pines, FL - Bay Pines

Georgia

  • Atlanta VA Medical and Rehab Center, Decatur, GA - Decatur

Illinois

  • Edward Hines Jr. VA Hospital, Hines, IL - Hines

Trial Details

FieldValue
Enrollment Target 673 participants
Start Date 2021-02-25
Est. Completion 2026-03-31
Phase Phase 3

Sponsor

VA Office of Research and Development

1,668 total trials

What the Registry Record Tells You About NCT03668041

The ClinicalTrials.gov registry entry for NCT03668041 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 673 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 166-participant average among 151 other Insomnia trials with a reported enrollment target (305% higher). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Insomnia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT03668041 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, North Carolina, Alabama.

Frequently Asked Questions

What is clinical trial NCT03668041 about?

NCT03668041 is a clinical study titled "National Adaptive Trial for PTSD Related Insomnia". Many Veterans with posttraumatic stress disorder (PTSD) have trouble sleeping or have frequent nightmares. So far, no medication has been approved for treatment of insomnia in PTSD. The purpose of this research study is to find out if taking medications called trazodone or eszopiclone can help decre...

What is the current status of trial NCT03668041?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 673 participants. The study started on 2021-02-25. Estimated completion is 2026-03-31.

What conditions does trial NCT03668041 study?

This clinical trial studies the following conditions: Insomnia.

What interventions are being tested in trial NCT03668041?

The interventions under investigation include: Placebo (OTHER), Trazodone (DRUG), Eszopiclone (DRUG).

Who is sponsoring clinical trial NCT03668041?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03668041 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insomnia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.